Opendata, web and dolomites


Next generation allergen immunotherapy based on specifically modified recombinant hypoallergens

Total Cost €


EC-Contrib. €






 AllergyVAX project word cloud

Explore the words cloud of the AllergyVAX project. It provides you a very rough idea of what is the project "AllergyVAX" about.

treatment    reduce    asthma    clinically    platform    serious    takes    injectable    tolerate    horse    shown    proteins    trigger    popularity    burden    missed    immunotherapy    reactions    rhinitis    few    preclinical    dozens    seamless    disease    trial    tolerated    candidates    pollen    allergies    immunological    global    economic    advancing    bet    ait    medication    immunogenicity    allergy    causes    temporarily    allergens    months    modifications    dose    symptom    establishing    allergyvax    building    rbet    allergic    small    shorten    alleviates    drugs    usually    natural    dm    tolerance    modifying    created    daily    human    compromising    injections    basis    dog    mice    allergen    pipeline    peanut    risk    efficacy    maximum    modified    avoiding    hypoallergens    symptomatic    fold    million    tests    birch    clinical    desired    relatively    release    training    people    hypoallergen    managed    monthly    patients    school    tablets    immune    histamine    relief    billion    grass    days    iia    symptoms    transition    social    drops    iib    launch    date   

Project "AllergyVAX" data sheet

The following table provides information about the project.


Organization address
postcode: 260
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 3˙684˙750 €
 EC max contribution 1˙885˙000 € (51%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2021-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DESENTUM OY FI (HELSINKI) coordinator 1˙885˙000.00


 Project objective

Allergy is a rapidly increasing, global problem that already affects 1 billion people and causes significant social and economic burden. In Europe, allergic rhinitis and asthma cause more than 100 million missed work and school days per year. Allergy is usually managed by avoiding the allergen or by medication that temporarily alleviates the symptoms. The only disease-modifying treatment available to date is allergen immunotherapy (AIT) where long-term symptom relief is achieved by training the immune system to tolerate allergens. However, typical AIT takes 3-5 years, involves monthly injections or daily drops/tablets and has the risk of serious allergic reactions during treatment. Thus, the popularity of AIT is still relatively low compared to symptomatic drugs. We have developed a platform technology for creating modified hypoallergens to be used in AIT. It is based on making small, highly targeted modifications to allergen proteins that reduce their ability to trigger allergic reactions during treatment without compromising their efficacy in building tolerance to natural allergens. With these modified hypoallergens, we expect to shorten the injectable AIT treatment from dozens of injections over 3 years to just 3-6 injections over a few months. From the clinically important major birch pollen allergen Bet v 1 we have created rBet v 1 dm hypoallergen. In preclinical tests it has shown 100-fold reduction in histamine release compared to natural allergens and induced similar immunological responses in mice that are desired in human AIT. In the AllergyVAX project we will test rBet v 1 dm for maximum tolerated dose and immunogenicity in allergic patients in a phase I/IIa clinical trial. The project will facilitate seamless transition to phase IIb-III clinical development, establishing a basis for product launch with selected partners and advancing other hypoallergens in the pipeline, including product candidates for grass pollen, dog, horse and peanut allergies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ALLERGYVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ALLERGYVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HAC (2019)


Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More